Golimumab -a new tool in the armoury against inflammatory arthritis

Annals of Medicine

Volumn 43, Issue 2, 2011, Pages 133-141

  Ash, Zoe ^a,b   Emery, Paul ^a,b  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Biological therapy; golimumab; monoclonal antibodies; psoriatic arthritis; rheumatoid arthritis; safety; treatment effi cacy; tumour necrosis factor alpha

Indexed keywords

GOLIMUMAB; METHOTREXATE; PLACEBO; TUMOR NECROSIS FACTOR ALPHA;

ANKYLOSING SPONDYLITIS; ARTICLE; DRUG BIOAVAILABILITY; DRUG HALF LIFE; HUMAN; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS;

ANIMALS; ANTIBODIES, MONOCLONAL; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79951575578     PISSN: 07853890     EISSN: 13652060     Source Type: Journal    
DOI: 10.3109/07853890.2010.549148     Document Type: Article

References (38)

1. Brennan FM, Maini RN, Feldmann M. TNF alpha - a pivotal role in rheumatoid arthritis? Br J Rheumatol. 1992;31:293-8.
2. Smolen JS, Han C, van der Heijde DM, Emery P, Bathon JM, Keystone E, et al. Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with meth-otrexate monotherapy and infl iximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. Ann Rheum Dis. 2009;68:823-7.
3. Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum. 2004;50:1400-11. (Pubitemid 38608061)
4. Van der Heijde D, Burmester G, Melo-Gomes J, Codreanu C, Martin Mola E, Pedersen R, et al. Inhibition of radiographic progression with combination etanercept and methotrexate in patients with moderately active rheumatoid arthritis previously treated with monotherapy. Ann Rheum Dis. 2009;68: 1113-8.
5. Anis A, Zhang W, Emery P, Sun H, Singh A, Freundlich B, et al. The effect of etanercept on work productivity in patients with early active rheumatoid arthritis: results from the COMET study. Rheumatology (Oxford). 2009;48:1283-9.
6. Van Vollenhoven RF, Cifaldi MA, Ray S, Chen N, Weisman MH. Improvement in work place and household productivity for patients with early rheumatoid arthritis treated with adali-mumab plus methotrexate: work outcomes and their correlations with clinical and radiographic measures from a randomized controlled trial companion study. Arthritis Care Res (Hoboken). 2010;62:226-34.
7. Saleem B, Keen H, Goeb V, Parmar R, Nizam S, Hensor EM, et al. Patients with RA in remission on TNF blockers: when and in whom can TNF blocker therapy be stopped? Ann Rheum Dis. 2010;69:1636-42.
8. Brown AK, Quinn MA, Karim Z, Conaghan PG, Peterfy CG, Hensor E, et al. Presence of signifi cant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic drug-induced clinical remission: evidence from an imaging study may explain structural progression. Arthritis Rheum. 2006;54:3761-73. (Pubitemid 44955876)
9. Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet. 2004;364:263-9. (Pubitemid 38942816)
10. Ling J, Lyn S, Xu Z, Achira M, Bouman-Thio E, Shishido A, et al. Lack of racial differences in the pharmacokinetics of subcutaneous golimumab in healthy Japanese and Caucasian male subjects. J Clin Pharmacol. 2010;50:792-802.
11. Zhou H, Jang H, Fleischmann RM, Bouman-Thio E, Xu Z, Marini JC, et al. Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis. J Clin Pharmacol. 2007;47: 383-96. (Pubitemid 46294717)
12. Xu Z, Wang Q, Zhuang Y, Frederick B, Ya n H, Bouman-Thio E, et al. Subcutaneous bioavailability of golimumab at 3 different injection sites in healthy subjects. J Clin Pharmacol. 2010; 50:276-84.
13. Kay J, Matteson EL, Dasgupta B, Nash P, Durez P, Hall S, et al. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum. 2008;58:964-75. (Pubitemid 351563997)
14. Visvanathan S, Wagner C, Rojas J, Kay J, Dasgupta B, Matteson EL, et al. E-selectin, interleukin 18, serum amyloid a, and matrix metalloproteinase 9 are associated with clinical response to golimumab plus methotrexate in patients with active rheumatoid arthritis despite methotrexate therapy. J Rheumatol. 2009;36:1371-9.
15. Kremer J, Ritchlin C, Mendelsohn A, Baker D, Kim L, Xu Z, et al. Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week effi cacy and safety results of a phase III randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2010;62: 917-28.
16. Emery P, Fleischmann RM, Moreland LW, Hsia EC, Strusberg I, Durez P, et al. Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcuta-neously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as fi rst-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum. 2009;60:2272-83.
17. Emery P, Fleischmann R, Van der Heijde D, Keystone E, Genovese MC, Conaghan PG, et al. The effect of golimumab on radiographic progression in rheumatoid arthritis: results of the GO-BEFORE and GO-FORWARD randomized, controlled studies. Arthritis Rheum. 2011; in press.
18. Keystone EC, Genovese MC, Klareskog L, Hsia EC, Hall ST, Miranda PC, et al. Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis. 2009;68:789-96.
19. Keystone E, Genovese MC, Klareskog L, Hsia EC, Hall S, Miranda PC, et al. Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study. Ann Rheum Dis. 2010;69: 1129-35.
20. Smolen JS, Kay J, Doyle MK, Landewe R, Matteson EL, Wollenhaupt J, et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet. 2009;
21. Kavanaugh A, McInnes I, Mease P, Krueger GG, Gladman D, Gomez-Reino J, et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week effi cacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum. 2009;60:976-86.
22. Kavanaugh A, van der Heijde D, Gladman D, Mease P, McInnes I, Krueger GG, et al. Golimumab inhibits progression of radiographic damage in patients with psoriatic arthritis: 52 week results from the GO-REVEAL study. ACR Abstract. 2009;LB5.
23. Kavanaugh A, Mease P, Krueger GG, Gladman D, Zrubek J, Beutler A, et al. Golimumab, a new, human, TNF alpha antibody, administered subcutaneously every 4 weeks in psoriatic arthritis patients: 104 week effi cacy and safety results of the randomised, placebo-controlled GO-REVEAL Study [conference abstract]. ACR Annual Meeting, Philadelphia, 2009. p. 512.
24. Inman RD, Davis JC Jr, Heijde D, Diekman L, Sieper J, Kim SI, et al. Effi cacy and safety of golimumab in patients with anky-losing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum. 2008;58: 3402-12.
25. Deodhar A, Braun J, Inman RD, Mack M, Parasuraman S, Buchanan J, et al. Golimumab reduces sleep disturbance in patients with active ankylosing spondylitis: Results from a randomized, placebo-controlled trial. Arthritis Care Res (Hoboken). 2010;62:1266-71.
26. Xu Z, Vu T, Lee H, Hu C, Ling J, Yan H, et al. Population pharmacokinetics of golimumab, an anti-tumor necrosis factor-alpha human monoclonal antibody, in patients with psoriatic arthritis. J Clin Pharmacol. 2009;49:1056-70.
27. Wenzel SE, Barnes PJ, Bleecker ER, Bousquet J, Busse W, Dahlen SE, et al. A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. Am J Respir Crit Care Med. 2009; 179:549-58.
28. Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum. 2004;50:1740-51. (Pubitemid 38725085)
29. Geborek P, Bladstrom A, Turesson C, Gulfe A, Petersson IF, Saxne T, et al. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis. 2005;64:699-703. (Pubitemid 40559295)
30. Askling J, Fored CM, Baecklund E, Brandt L, Backlin C, Ekbom A, et al. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis. 2005; 64:1414-20. (Pubitemid 41623850)
31. Food and Drug Administration. Highlights of prescribing information. 2009. Available at: http://www.accessdata. fda.gov/drugsatfda-docs/label/2009/ 125289s006lbl.pdf. Accessed date 8 June 2010.
32. Cush JJ. Early rheumatoid arthritis - is there a window of opportunity? J Rheumatol Suppl. 2007;80:1-7. (Pubitemid 350076862)
33. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2000;343:1586-93. (Pubitemid 32162981)
34. Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54:26-37. (Pubitemid 43122183)
35. Emery P, Breedveld FC, Hall S, Durez P, Chang DJ, Robertson D, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet. 2008;372:375-82.
36. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum. 2005;52: 3381-90. (Pubitemid 41612204)
37. Quinn MA, Conaghan PG, O ' Connor PJ, Karim Z, Greenstein A, Brown A, et al. Very early treatment with infl iximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefi t after infl iximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2005;52:27-35. (Pubitemid 40129229)
38. St Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, et al. Combination of infl iximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum. 2004;50:3432-43. (Pubitemid 39488667)